S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
NASDAQ:LXRX

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$2.36
-0.10 (-4.07%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.35
$2.45
50-Day Range
$1.80
$2.46
52-Week Range
$1.31
$3.48
Volume
275,893 shs
Average Volume
318,565 shs
Market Capitalization
$445.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
535.6% Upside
$15.00 Price Target
Short Interest
Bearish
2.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.39 out of 5 stars

Medical Sector

960th out of 1,028 stocks

Pharmaceutical Preparations Industry

467th out of 501 stocks

LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+323.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-87,760,000.00
Net Margins
-77,648.80%
Pretax Margin
-77,648.80%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$0.76 per share

Miscellaneous

Free Float
176,459,000
Market Cap
$445.40 million
Optionable
Optionable
Beta
1.38

Social Links


Key Executives

  • Lonnel Coats
    Chief Executive Officer & Director
  • Jeffrey L. Wade
    President & Chief Financial Officer
  • Craig B. Granowitz
    Chief Medical Officer & Senior Vice President
  • Brian T. Crum
    Secretary, Senior Vice President & General Counsel
  • Kiernan A. Seth
    Chief Commercial Officer & Vice President













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2023?

2 brokers have issued 12-month price targets for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 535.6% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2023?

Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of 2023. Since then, LXRX shares have increased by 23.6% and is now trading at $2.36.
View the best growth stocks for 2023 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative net margin of 77,648.80% and a negative trailing twelve-month return on equity of 92.19%.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.05%), Pinnacle Associates Ltd. (1.02%), Fisher Asset Management LLC (0.38%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), SG Americas Securities LLC (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends
.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.36.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $445.40 million and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-87,760,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 2/5/2023 by MarketBeat.com Staff